Genetic susceptibility of diffuse large B-cell lymphoma: a meta genome-wide association study in Asian population: LYMPHOMA

Qian Cui, Wen Tan, Bao Song, Rou Jun Peng, Ling Wang, Rajkumar Dorajoo, Kok Pin Ng, Guo Wang Lin, Wing Yan Au, Raymond H.S. Liang, Chiea Chuen Khor, Qing Ling Zhang, Jia Nee FOO, Sheng Ping Li, Fu Ren Zhang, Xue Jun Zhang, Xue Qing Yu, Qing Lan, Stephen Chanock, Wei Hua JiaSoon Thye Lim, Wen Yu Li, Nathaniel Rothman, Jin Xin Bei, Jie Liu, Dongxin Lin, Jian Jun Liu*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy and the most common form of non-Hodgkin lymphoma (NHL) that occurs worldwide. To discover risk factors and pathogenesis of DLBCL, we performed the largest GWAS of DLBCL to date in samples of East Asian ancestry, consisting of 2,888 patients with DLBCL and 12,458 controls. The meta-analysis identified three novel loci, rs2233434 on 6p21.1 (OR = 1.26, P = 1.17 × 10−8), rs11066015 on 12q24.12 (OR = 1.24, P = 6.57 × 10−9) and rs6032662 on 20q13.12 (OR = 1.24, P = 5.22 × 10−12). Fine mapping analysis revealed that the extensive association within the MHC region was driven by two novel HLA alleles, HLA-A*02 and HLA-DQB1*03. Functional annotation, eQTL and colocalization analyses of the susceptibility loci implicated NFKBIE/TCTE1, ALDH2/BRAP and CD40 as candidate disease genes. The pleiotropic effect analysis of the DLBCL loci revealed shared genetic susceptibility between DLBCL and several autoimmune diseases. Our study also suggested genetic heterogeneity between Asian and European populations by identifying ancestry-specific genetic associations. Overall, this study has implicated novel disease genes and molecular mechanism for DLBCL.

Original languageEnglish
Article number1826
JournalLeukemia
DOIs
Publication statusAccepted/In press - 2024
Externally publishedYes

Bibliographical note

Publisher Copyright:
© The Author(s), under exclusive licence to Springer Nature Limited 2024.

ASJC Scopus Subject Areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this